CD&D Catheter and Continence Formulary - May 2018
Tees Guidance on Prescribing Continence Appliances in General Practice
NICE CG97: Lower urinary tract symptoms in men: assessment and management
NICE NG118: Renal and ureteric stones: assessment and management
NICE NG123: Urinary incontinence and pelvic organ prolapse in women: management
NICE NG126: Ectopic pregnancy and miscarriage: diagnosis and initial management
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
CD&D Patient Decision Aids Resource available at: http://medicines.necsu.nhs.uk/guidelines/durham-darlington/
NHS England Guidance on “Conditions for which over the counter items should not routinely be prescribed” available at: https://www.england.nhs.uk/medicines/conditions-for-which-over-the-counter-items-should-not-routinely-be-prescribed/
Prescribing of medicines available to purchase over the counter for self-care
0.75mg in 0.75ml injections
3mg vaginal tablets
10mg pessary
Drug protocol: neonatal prostaglandin infusion (CDDFT intranet access only)
a) Candidiasis
First Choice = Clotrimazole
b) Other Infections
Metronidazole Vaginal Gel
Clindamycin Vaginal Cream
Guidelines:
NICE CG30: Long-acting reversible contraception
MHRA Drug Safety Update (June 2015): Intrauterine contraception: uterine perforation—updated information on risk factors
MHRA Drug Safety Update (March 2014) – Interaction of hormonal contraceptives with St John’s Wort
Please note that the examples of brands listed below include the most cost-effective at the time of publication of this chapter (May 2017) and the current most cost-effective brand for primary or secondary care should be prescribed where possible.
MHRA Drug Safety Update (March 2014) – risk of VTE
Please note that the examples of brands listed below include the most cost-effective at the time of publication of this chapter (May 2017) and the current most cost-effective brand for primary or secondary care should be prescribed where possible.
The first line combined hormonal contraceptive for all women requiring CHC.
First line
(Note: In County Durham the Sexual Health Service choice is Maexeni 150/30)
Second line (alternative progesterone)
Third line (slightly higher oestrogen content therefore helpful if vaginal dryness is affecting libido)
Norgestimate 250micrograms with ethinylestradiol 35micrograms – Lizinna
(Note: In County Durham the Sexual Health Service choice is Cilest)
Fourth line (these oral preparations contain the third generation progesterones gestodene, desogestrel and drosperidone and therefore carry an increased risk of VTE compared to second generation progesterones. They should be reserved for women who are intolerant of other CHCs. These products are usually reserved for women who have progestogenic side effects on a first line pill and so need a more oestrogen-dominant pill. Due to the increased VTE risk the patient must be made aware before prescribing)
(Note: In County Durham the Sexual Health Service choice is Aidulan 30/75)
(Note: In County Durham the Sexual Health Service choice is Munalea 150/30)
(Note: In County Durham the Sexual Health Service choice is Yiznell)
Brand names include Rigevidon and Microgynon 30
(Note: In County Durham the Sexual Health Service choice is Maexeni 150/30)
IVF only = Ovranette®
Brand = Brevinor
Brands include Lizinna.
(Note: In County Durham the Sexual Health Service choice is Cilest)
Brands include Millinette.
(Note: In County Durham the Sexual Health Service choice is Aidulan 30/75)
Brands include Gedarel 30/150
(Note: In County Durham the Sexual Health Service choice is Munalea 150/30)
Please note that the examples of brands listed below include the most cost-effective at the time of publication of this chapter (May 2017) and the current most cost-effective brand for primary or secondary care should be prescribed where possible.
Low dose oestrogen content (consider switching to a product with a lower oestrogen component if there is significant nausea / vomiting. Be aware that these products may be less effective at inhibiting ovulation compared to products with a higher oestrogen component and are also more likely to have breakthrough bleeding)
The following low dose oestrogren oral preparations contain third generation progesterones and therefore carry an increased risk of VTE. They should be reserved for women who are intolerant of other CHCs:
(Note: In County Durham the Sexual Health Service choice is Aidulan 20/75)
(Note: In County Durham the Sexual Health Service choice is Munalea 20/150)
Brand = Millinette
(Note: In County Durham the Sexual Health Service choice is Aidulan 20/75)
For patients at risk of 'missed pills' and for those with persistent breakthrough bleeding (where other causes have been excluded). These products contain ethinylestridiol and levonorgestrel in varying amounts to correspond with each “phase”
6 Ethinylestradiol 30 microg. & levonorgestrel 50 microg. + 5 Ethinylestradiol 40 microg. & levonorgestrel 75 microg. + 10 ethinylestradiol 30 microg. & levonorgestrel 125 microg.
For use by a small number of women with gastrointestinal absorption problems or with compliance issues. The contraindications for CHC are the same for oral and transdermal preparations.
Evra patch is approximately 7x the cost of the first line oral ethinylestradiol 30micrograms / levonogestrel 150micrograms preparations.
NICE CG30 - Long-acting reversible contraception
Please note that the examples of brands listed below that are highlighted in green include the most cost-effective at the time of publication of this chapter (May 2017).
7.3.2a Oral Progestogen-Only Contraceptives
First line (preferred due to 12 hour window to take a missed pill, compared to 3 hours with alternative progesterones)
(Note: The Sexual Health Service choice is Feanolla)
Alternative progesterones
7.3.2b Parenteral Progestogen-Only Contraceptives
Replaced Implanon and differs in that it is impregnated with radio opaque material.
Medroxyprogesterone
7.3.2c Levonorgestrel Intra-Uterine System
Prescribe by brand to ensure correct replacement time period:
Levonorgestrel-releasing intrauterine systems: prescribe by brand name. Drug Safety Update January 2016. MHRA. www.gov.uk/drug-safety-update/levonorgestrel-releasing-intrauterine-systems-prescribe-by-brand-name)
Prescribe generically in most cases. N.B. Consider prescribing by brand in patients with soya or nut allergy as some generics may contain ingredients unsuitable for soya or nut allergy sufferers - check individual SPC.
First line (preferred due to 12 hour window to take a missed pill, compared to 3 hours with alternative progesterones)
(Note: In County Durham the Sexual Health Service choice is Feanolla)
Alternative progesterones
Brands include Cerazette and Cerelle
(Note: The Sexual Health Service choice is Feanolla)
Prescribe generically in most cases. N.B. Consider prescribing by brand in patients with soya or nut allergy as some generics may contain ingredients unsuitable for soya or nut allergy sufferers - check individual SPC.
Replaced Implanon and differs in that it is impregnated with radio opaque material.
Medroxyprogesterone
Intramuscular preparation - Depo-Provera 150mg
Subcutaneous preparation (consider this preparation when unsure if needle will reach the muscle, or if there is very little muscle) - Sayana Press 104mg
MHRA Drug Safety Update (Jan 2016): Levonorgestrel-releasing intrauterine systems: prescribe by brand name
68mg implant (Nexplanon® )
Replaced Implanon and differs in that it is impregnated with radio opaque material.
MHRA Drug Safety Update (June 2016): Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung
MHRA Drug Safety Update (Feb 2020): Nexplanon (etonogestrel) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury and implant migration
Prescribe by brand to ensure correct replacement time period:
Levonorgestrel-releasing intrauterine systems: prescribe by brand name. Drug Safety Update January 2016. MHRA. www.gov.uk/drug-safety-update/levonorgestrel-releasing-intrauterine-systems-prescribe-by-brand-name)
IUD
MHRA Drug Safety Update (Jan 2016): Levonorgestrel-releasing intrauterine systems: prescribe by brand name
5 year contraceptive protection
20 micrograms/24 hours Intrauterine Delivery System
The intrauterine delivery system contains 52 mg levonorgestrel.
4 year contraceptive protection.
MHRA Drug Safety Update (Jan 2016): Levonorgestrel-releasing intrauterine systems: prescribe by brand name
IUD
Only be used for women who require a smaller IUD than Mirena.
MHRA Drug Safety Update (Jan 2016): Levonorgestrel-releasing intrauterine systems: prescribe by brand name
5 year contraceptive protection.
MHRA Safety Warning – June 2015 - Intrauterine contraception: uterine perforation—updated information on risk factors
First line - 5 year replacement
Second line - 10 year replacement
Emergency contraception. FSRH guideline. March 2017. www.fsrh.org/standards-and-guidance/current-clinical-guidance/emergency-contraception/
Please note that the examples of brands listed below that are highlighted in green include the most cost-effective at the time of publication of this chapter (May 2017).
7.3.5a Emergency Oral Hormonal Contraception (EOHC)
A Copper Interuterine Contraception Device (Cu-IUCD) is the most effective form of emergency contraception and should be the first line method for most women (pregnancy rate <0.1%). For those women who decline or are deemed unsuitable for Cu-IUCD insertion, selection of the most appropriate EOHC should not just be based on hours since unprotected sexual intercourse (UPSI) but be dependent on a risk assessment including:
See FSRH emergency contraception guideline at www.fsrh.org/standards-and-guidance/current-clinical-guidance/emergency-contraception/ for further information and decision analysis algorithms.
Brands include Upostelle.
MHRA Drug Safety Update (Sept 2016): Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy.
(N.B. Elevated levels of CYP3A4 enzymes can persist for up to 4 weeks after cessation of the enzyme-inducing medicine. This decrease in plasma levonorgestrel may reduce contraceptive efficacy of levonorgestrel-containing emergency hormonal contraceptives).
Pack containing one ulipristal acetate 30mg tablet.
Brands include Ellaone
Ulipristal (EllaOne): see NTAG recommendation – is recommended as the preferred drug treatment option for post-coital contraception for patients who present between 72 and 120 hours following unprotected intercourse. Levonorgestrel is still recommended for patients who present at up to 72 hours following unprotected intercourse.
MR Capsules - 400microgram
Tamsulosin capsules are the preferred formulation. The use of tablets should be avoided.
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
Tablets - 2.5mg, 3mg, 5mg
THIRD LINE
Transdermal Patch - 3.9mg/24hours
Immediate release formulations are first choice. Modified release formulations should not be used.
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
Tablets - 25mg, 50mg
Mirabegron: NICE TA290
Only in patients intolerant of anticholinergics, contraindicated or ineffective
MHRA Drug Safety Update (Oct 2015): Mirabegron - risk of severe hypertension and associated cerebrovascular and cardiac events
Duloxetine: for the treatment of stress incontinence it may be offered as 2nd line therapy in combination with pelvic floor muscle training in women who prefer pharmacological to surgical treatment or are not suitable for surgical treatment. If duloxetine is prescribed, women should be counselled about its adverse effects
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
Vesomni 6mg/400mcg
Rejected by JCUH D&T 5/11/14 due to lack of evidence of benefit, and debate over cost savings. Darifenacin's patent expires Feb 2015
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
Vaginal Devices for female stress urinary incontinence
(e.g. Diveen, Contiform, Efemia)
NTAG June 2020:The Northern (NHS) Treatment Advisory Group does not recommend the use of Vaginal devices (e.g. Diveen®, Contiform® and Efemia®) for the management of female urinary stress incontinence on the NHS. Should patients wish to use these devices they can be purchased over the counter for occasional use, for example during exercise The group was concerned that there is a lack of quality evidence currently to support the efficacy of these devices and their use is not currently recommended in NICE guidelines.
100 & 200 microgram tablets
120 microgram sublingual tablets
Nasal formulations no longer licensed for treating nocturnal enuresis.
25 microgram and 50 micromgram oral lyophilisate tablets
Indicated for symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.
GP Information leaflet to support prescribing available at: http://medicines.necsu.nhs.uk/guidelines/durham-darlington/
50mg capsules
MHRA Drug Safety Update (Sept 2019): Elmiron (pentosan polysulfate sodium): rare risk of pigmentary maculopathy
40mg in 50ml solution for instillation into the bladder (Cystistat®)u
Catheter patency solution
0.02% (1 in 5,000) solution in 100ml sachets
Catheter patency solution
0.9% solution in 100ml sachets
Urotainer Twin Suby G®
2 x 30ml sachets (citric acid 3.23%, magnesium oxide 0.38%,
sodium bicarbonate 0.7%, disodium edetate 0.01%)
See CD&D APC GUIDELINES FOR MANAGEMENT OF ERECTILE DYSFUNCTION (ED) IN ADULTS (≥ 18 YEARS)
Daily vs on-demand PDE-5 inhibitors for mangement of erectile dysfunction following treatment for prostate cancer:
There is no evidence to recommend the use of daily dosing over on-demand dosing of PDE5 inhibitors, and there was no evidence that tadalafil was superior to sildenafil. On this basis NTAG recommends on demand dosing using PDE5 inhibitor with the lowest acquistion cost, currently this is generic sildenafil.
Injection - 5 microgram, 10 microgram, 20 microgram, 40 microgram
Urethral Application (MUSE) - 250 microgram, 500 microgram, 1mg
Tablets - 25mg, 50mg, 100mg
Treatment of pulmonary hypertension and secondary Raynaud’s disease is specialist only - see Chapter 2
MHRA Drug Safety Update (Nov 2018): Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
Aviptadil 25microgram/phentolamine 2mg solution for injection (Invicorp®)
Approved for the 3rd line treatment option for erectile dysfunction as an alternative to intracaversonal alprostadil in patients who have failed PDE5 inhibitors.
Place in therapy is as an alternative to intracaversonal alprostadil due to lack of efficacy or side-effects in patients who have failed PDE5 inhibitors.
See CD&D GUIDELINES FOR MANAGEMENT OF ERECTILE DYSFUNCTION (ED) IN ADULTS (≥ 18 YEARS)
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
The Northern (NHS) Treatment Advisory Group does not recommend the use of dapoxetine for premature ejaculation.
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/